219 related articles for article (PubMed ID: 31571343)
1. Long-term observation on hepatitis B surface antigen seroclearance in therapy experienced HIV/HBV co-infected Chinese.
Yang R; Gui X; Ke H; Xiong Y; Gao S
J Viral Hepat; 2020 Feb; 27(2):127-134. PubMed ID: 31571343
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa.
Boyd A; Maylin S; Moh R; Mahjoub N; Gabillard D; Eholié SP; Danel C; Anglaret X; Zoulim F; Girard PM; Delaugerre C; Lacombefor K;
J Gastroenterol Hepatol; 2016 Mar; 31(3):634-44. PubMed ID: 26313291
[TBL] [Abstract][Full Text] [Related]
3. Incidence and factors associated with hepatitis B surface antigen seroclearance in patients co-infected with HBV/HIV during antiretroviral therapy in Guangdong, China.
He Y; Lin W; Li H; Gu F; Zhong H; Lan Y; Li Y; Guo P; Hu F; Cai W; Tang X; Li L
Chin Med J (Engl); 2023 Nov; 136(22):2686-2693. PubMed ID: 37881959
[TBL] [Abstract][Full Text] [Related]
4. Precore G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus co-infected patients from Western Africa.
Boyd A; Moh R; Maylin S; Abdou Chekaraou M; Mahjoub N; Gabillard D; Anglaret X; Eholié SP; Delaugerre C; Danel C; Zoulim F; Lacombe K;
J Viral Hepat; 2018 Oct; 25(10):1121-1131. PubMed ID: 29660214
[TBL] [Abstract][Full Text] [Related]
5. Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV-/HBV-coinfected patients.
Strassl R; Reiberger T; Honsig C; Payer BA; Mandorfer M; Grabmeier-Pfistershammer K; Rieger A; Kundi M; Grundtner P; Peck-Radosavljevic M; Popow-Kraupp T
J Viral Hepat; 2014 Jul; 21(7):508-16. PubMed ID: 24112778
[TBL] [Abstract][Full Text] [Related]
6. HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.
Hamers RL; Zaaijer HL; Wallis CL; Siwale M; Ive P; Botes ME; Sigaloff KC; Hoepelman AI; Stevens WS; Rinke de Wit TF;
J Acquir Immune Defic Syndr; 2013 Oct; 64(2):174-82. PubMed ID: 23892239
[TBL] [Abstract][Full Text] [Related]
7. Rates and determinants of hepatitis B 'e' antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus.
Boyd A; Gozlan J; Miailhes P; Lascoux-Combe C; Cam MS; Rougier H; Zoulim F; Girard PM; Lacombe K
AIDS; 2015 Sep; 29(15):1963-73. PubMed ID: 26153669
[TBL] [Abstract][Full Text] [Related]
8. Long-term Hepatitis B and Liver Outcomes Among Adults Taking Tenofovir-Containing Antiretroviral Therapy for HBV/HIV Coinfection in Zambia.
Vinikoor MJ; Hamusonde K; Muula G; Asombang M; Riebensahm C; Chitundu H; Sunkuntu-Sichizya V; Bhattacharya D; Sinkala E; Lauer G; Chung R; Mbewe W; Egger M; Bosomprah S; Wandeler G
Clin Infect Dis; 2024 Jun; 78(6):1583-1590. PubMed ID: 37997691
[TBL] [Abstract][Full Text] [Related]
9. Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV.
Boyd A; Maylin S; Gozlan J; Delaugerre C; Simon F; Girard PM; Lacombe K
Liver Int; 2015 Mar; 35(3):795-804. PubMed ID: 24606220
[TBL] [Abstract][Full Text] [Related]
10. The kinetics of the hepatitis B surface antigen level after the initiation of antiretroviral therapy for hepatitis B virus and human immunodeficiency virus coinfected patients.
Mitsumoto F; Murata M; Ura K; Takayama K; Hiramine S; Shimizu M; Toyoda K; Ogawa E; Furusyo N; Hayashi J
J Infect Chemother; 2015 Apr; 21(4):264-71. PubMed ID: 25596071
[TBL] [Abstract][Full Text] [Related]
11. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment.
Seto WK; Liu K; Wong DK; Fung J; Huang FY; Hung IF; Lai CL; Yuen MF
J Hepatol; 2013 Oct; 59(4):709-16. PubMed ID: 23792029
[TBL] [Abstract][Full Text] [Related]
12. Lamivudine plus tenofovir versus lamivudine plus adefovir for the treatment of hepatitis B virus in HIV-coinfected patients, starting antiretroviral therapy.
Sarkar J; Saha D; Bandyopadhyay B; Saha B; Chakravarty R; Guha SK
Indian J Med Microbiol; 2018; 36(2):217-223. PubMed ID: 30084414
[TBL] [Abstract][Full Text] [Related]
13. Persistent HBV replication and serological response during up to 15 years of tenofovir-based antiretroviral therapy in HIV/HBV-coinfected patients: a multicentre prospective cohort study.
Dezanet LNC; Miailhes P; Lascoux-Combe C; Chas J; Maylin S; Gabassi A; Rougier H; Delaugerre C; Lacombe K; Boyd A
J Antimicrob Chemother; 2021 Oct; 76(11):3009-3019. PubMed ID: 34458919
[TBL] [Abstract][Full Text] [Related]
14. Virological responses to tenofovir-alafenamide-containing antiretroviral therapy in people living with HIV co-infected with lamivudine-resistant or lamivudine-susceptible hepatitis B virus.
Huang YS; Sun HY; Chang SY; Chuang YC; Su YC; Liu WC; Hung CC
Int J Antimicrob Agents; 2022; 60(5-6):106682. PubMed ID: 36279976
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV.
Zoutendijk R; Zaaijer HL; de Vries-Sluijs TE; Reijnders JG; Mulder JW; Kroon FP; Richter C; van der Eijk AA; Sonneveld MJ; Hansen BE; de Man RA; van der Ende ME; Janssen HL
J Infect Dis; 2012 Sep; 206(6):974-80. PubMed ID: 22782950
[TBL] [Abstract][Full Text] [Related]
16. Lamivudine Monotherapy-Based cART Is Efficacious for HBV Treatment in HIV/HBV Coinfection When Baseline HBV DNA <20,000 IU/mL.
Li Y; Xie J; Han Y; Wang H; Zhu T; Wang N; Lv W; Guo F; Qiu Z; Li Y; Du S; Song X; Thio CL; Li T
J Acquir Immune Defic Syndr; 2016 May; 72(1):39-45. PubMed ID: 26745828
[TBL] [Abstract][Full Text] [Related]
17. Intensification with pegylated interferon during treatment with tenofovir in HIV-hepatitis B virus co-infected patients.
Boyd A; Piroth L; Maylin S; Maynard-Muet M; Lebossé F; Bouix C; Lascoux-Combe C; Mahjoub N; Girard PM; Delaugerre C; Carrat F; Lacombe K; Miailhes P
J Viral Hepat; 2016 Dec; 23(12):1017-1026. PubMed ID: 27486094
[TBL] [Abstract][Full Text] [Related]
18. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.
Seto WK; Wong DK; Fung J; Huang FY; Lai CL; Yuen MF
Hepatology; 2013 Sep; 58(3):923-31. PubMed ID: 23468172
[TBL] [Abstract][Full Text] [Related]
19. Effect of hepatitis B virus (HBV) surface-gene variability on markers of replication during treated human immunodeficiency virus-HBV infection in Western Africa.
Boyd A; Moh R; Maylin S; Abdou Chekaraou M; Mahjoub N; Gabillard D; Anglaret X; Eholié SP; Danel C; Delaugerre C; Zoulim F; Lacombe K;
Liver Int; 2019 Feb; 39(2):280-289. PubMed ID: 30257068
[TBL] [Abstract][Full Text] [Related]
20. Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy.
Lewin SR; Ribeiro RM; Avihingsanon A; Bowden S; Matthews G; Marks P; Locarnini SA; Ruxrungtham K; Perelson AS; Dore GJ
Hepatology; 2009 Apr; 49(4):1113-21. PubMed ID: 19115219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
